Researchers from Monte Rosa Therapeutics Inc. reported preclinical efficacy data on MRT-8102, a selective NEK7 molecular glue degrader, designed to treat inflammatory diseases.
WPC W. P. Carey Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback